Precipio

Precipio CapEx/D&A

CapEx to Depreciation Ratio of Precipio (PRPO) as of Oct 19, 2026.

CapEx/D&A

-

Last updated:

CapEx to Depreciation Ratio of Precipio is 2026 - . CapEx to Depreciation Ratio of Precipio was 2025 - . It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Precipio Stock analysis

What does Precipio do? Precipio Inc, headquartered in Omaha, Nebraska, is a health care company specializing in cancer diagnostics. The company develops and provides a platform aimed at reducing misdiagnosis through technologies like IV-Cell, a universal culture media for hematopoietic cell lineages, and HemeScreen, a rapid gene screening panel. Precipio's platform enables physicians to access necessary diagnostic tools for accurate patient diagnoses. Listed on July 18, 2000, the company employs 61 full-time staff. Precipio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Precipio stock

On Eulerpool you can find the complete historical development of CapEx to Depreciation Ratio Precipio since 2006 – with annual values, charts, and detailed analysis.

The CapEx/D&A ratio compares investment spending to asset depreciation. Ratios above 1.0x indicate the company is growing its asset base, below 1.0x suggests underinvestment.

A 'good' varies by industry and company stage. On Eulerpool, you can compare CapEx to Depreciation Ratio's Precipio with sector peers and the industry average to assess whether it is attractive.

To evaluate CapEx to Depreciation Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for CapEx to Depreciation Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Precipio

All Key Metrics — Precipio